Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S7.32
P/E—
Fwd P/E34.70
PEG2.62
52W— – —
RSI—
Target$405.38 (+17.1%)
Beta1.14
Div0.25%
Loading chart…
RSI ()
Loading patterns…
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 51
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
4Bullish
5Bearish
0Neutral
Key Signals 1
▼ Double Top
Major reversal
2026-08-28 · $343.48
Two peaks ~$359.48 — bearish reversal confirmed
Learn more →
Momentum Signals 8
▲ MACD Bullish Crossover
▲ Bull Flag
▲ Bull Flag
▲ MACD Bullish Crossover
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
STRONG BUY
BuyHoldSell
Price Target Range
$405.38
+17.1% upside
Low $340
—
High $459
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
36.79%Last 12 Months
Operating Margin
22.47%Last 12 Months
Return on Equity
19.09%Last 12 Months
Revenue Growth
13.80%Year over Year
Free Cash Flow
277.94MLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
10.59Most Recent Quarter
Current Ratio
2.82Most Recent Quarter
Cash
435.80MMost Recent Quarter
Total Debt
316.50MMost Recent Quarter
Net Debt
—Most Recent Quarter
How WST Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 24.37B |
| Enterprise Value | 24.25B |
| Trailing P/E | 44.05 |
| Forward P/E | 34.70 |
| PEG Ratio (5yr) | 2.62 |
| Price/Sales (ttm) | 7.32 |
| Price/Book (mrq) | 8.15 |
| EV/Revenue | 7.29 |
| EV/EBITDA | 26.58 |
Share Statistics
| Avg Vol (3m) | 691.32K |
| Shares Outstanding | 70.38M |
| Float | 69.86M |
| % Held by Insiders | 0.64% |
| % Held by Institutions | 101.96% |
| Short Ratio | 4.33 |
| Short % of Float | 3.65% |
Profitability
| Gross Margin | 36.79% |
| Operating Margin (ttm) | 22.47% |
| Profit Margin | 16.98% |
| Return on Assets (ttm) | 11.38% |
| Return on Equity (ttm) | 19.09% |
Income Statement
| Revenue (ttm) | 3.33B |
| Revenue Growth (yoy) | 13.80% |
| Gross Profit (ttm) | 1.22B |
| EBITDA | 912.20M |
| Net Income (ttm) | 564.90M |
| Diluted EPS (ttm) | 7.86 |
| EPS Growth (yoy) | 18.10% |
Balance Sheet
| Total Cash (mrq) | 435.80M |
| Total Debt (mrq) | 316.50M |
| Debt / Equity (mrq) | 10.59 |
| Current Ratio (mrq) | 2.82 |
| Book Value / Share | 42.47 |
| Operating CF (ttm) | 662.20M |
| Free Cash Flow (ttm) | 277.94M |
Trading & Dividends
| Beta (5Y) | 1.14 |
| 50-Day MA | 349.21 |
| 200-Day MA | 294.94 |
| Fwd Dividend Yield | 0.26% |
| Payout Ratio | 11.14% |
Income
Dividend Yield
0.25%Last 12 Months
Annual Rate
0.88Forward
Payout Ratio
11.14%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 11.14%
Monthly Dividends
Ownership Breakdown
Institutional 101.96%
Insider 0.64%
Short Interest
3.65% of float
Moderate
Institutional 13F Holdings
Famous investors who disclosed a position in WST in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|